RMD Open · 2015 · 13 citations · 18 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDrug RepurposingRheumatologyChronic Disease PharmacotherapyJoint DiseaseResponse AssessmentRheumatoid ArthritisDisease Activity MeasurementRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis TherapyTaper EffectsTime-dependent Covariate ModelingTreatment Effectiveness AnalysisTreatment Effectiveness MeasurementTumor Necrosis Factor Inhibitor Therapy
OBJECTIVES: To study the number of patients that taper or discontinue concomitant methotrexate (MTX) in daily practice in patients with rheumatoid arthritis (RA) treated with tumour necrosis factor inhibitor (TNFi) and to analyse the effects of that adaption on disease activity and drug survival. METHODS: Data were collected from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Patients who started their first TNFi were included in the study. Treatment effectiveness after MTX tapering or discontinuation was analysed using Disease Activity Score of 28 joints (DAS28). Drug survival of the TNFi was analysed using the Cox proportional hazard model with a time-dependent covariate. RESULTS: In 458 patients (34%), MTX was tapered, 126 patients (10%) discontinued MTX and 747 patients (56%) continued MTX at the same dose. On average, DAS28 improved after tapering MTX (-0.40, -0.45) and after stopping MTX (-0.28, -0.12) at 6 and 12 months. In the taper group, 21% of the patients relapsed (DAS28 increase >0.6), and in the discontinuation group this was 21% and 24% at 6 and 12 months, respectively. Patients who taper and discontinue MTX have a similar DAS28 score over time as patients who continue MTX. Moreover, there was no influence of tapering or discontinuation of MTX on long-term drug survival of TNFi. CONCLUSIONS: In daily practice, tapering or discontinuation of concomitant MTX in patients with RA treated with TNFi frequently occurs and it does not seem to influence the average DAS28 over time or the long-term TNFi drug survival. It appears that in daily clinical practice the correct patients are selected to taper or discontinue MTX.
18
Revised Criteria for the Classification of Rheumatoid Arthritis
Frank C. Arnett · Orthopaedic Nursing · 1990 · 7.7K citations
M.L.L. Prevoo, Martin A. van't Hof, H. H. Kuper et al. · Arthritis & Rheumatism · 1995 · 6.2K citations
Measurement of patient outcome in arthritis
James F. Fries, Patricia W. Spitz, R. Guy Kraines et al. · Arthritis & Rheumatism · 1980 · 4.4K citations
Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh et al. · Arthritis & Rheumatism · 2005 · 1.8K citations